Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept in ANA-positive rheumatoid arthritis
ChiCTR2100053713Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Wenzhou Medical University
- Start
- Dec 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of abatacept in rheumatoid arthritis (RA), sponsored by The First Affiliated Hospital of Wenzhou Medical University. Primary endpoint: ACR20 response at 24 weeks. Started Dec 2021; status: recruiting.
02
Drugs
abatacept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ChiCTR2100053713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053713.